QUARTER-END POSITION / VERSION 1

COYA.

COYA THERAPEUTICS INC

published

Reporting manager: DME Capital Management, LP
Relationship: Associated institution
Record date: 31 Mar 2026
Date meaning: Original Form 13F report period
Quantity: 2,335,540 shares
Reported value / amount: $9,202,027
Weight and denominator: 0.29% · Calculated: issuer/class value divided by the complete original reported table; not personal wealth
Quarter-end reported price: Not disclosed · Price at record date, not purchase cost
Derived value per reported unit: $3.94 · Reported value ÷ reported quantity (shares); not an observed market price
Source-reported activity: Not disclosed
Coverage: Complete original information table grouped by CUSIP and security class
Reviewed by: DeepSeek AI
Published: 20 Oct 2026

Original regulatory disclosure; 2 original filing line(s) grouped within this issuer/class. Absence from a disclosed table is not private account verification.

Reporting-entity association: Inspect the identity evidence

Display-code lookup: Display-code lookup, separate from numerical facts independently parsed from the original disclosure.

Original filing attribution · 2 line(s)

Reporting manager: DME Capital Management, LP. 13F HOLDINGS REPORT. These are reported investment-discretion relationships, not proof of beneficial ownership or a personal account. Each original line is counted once, including lines naming multiple managers.

Other included managers: 1 / DME Advisors, LP · CIK 0001300763; 2 / Greenlight Masters, LLC · CIK 0001449674.

ORIGINAL LINE	REPORTED QUANTITY / VALUE	OTHER MANAGER / DISCRETION	VOTING AUTHORITY
18	1,946,079 shares$7,667,551	No included manager referencedOriginal field: Not stated · Discretion: SOLE	Sole 1,946,079Shared 0 · None 0
19	389,461 shares$1,534,476	DME Advisors, LP · CIK 0001300763Original field: 1 · Discretion: OTR	Sole 389,461Shared 0 · None 0

View quotation / manual copy ↗

Editorial note: Independent AI source review 2026-10-21T01:14:31+08:00; batch 84ff3bef5309de8f14a7546bb791f49ef2ade43940716054032ffe7e789ec8ba. Original filing quantities, metadata and row attribution checked. Holdings facts only; corporate-action and period comparisons are not reviewed. This is AI review, not a human or private-account audit.

Sources.

Original disclosure

DME Capital Management, LP — 13F-HR — 2026-03-31

U.S. SEC EDGAR · Published 15 May 2026 · Collected 20 Oct 2026

Details ↗Open in the source library ↗

Version history.

Version 1published · 20 Oct 2026

Independent AI source review 2026-10-21T01:14:31+08:00; batch 84ff3bef5309de8f14a7546bb791f49ef2ade43940716054032ffe7e789ec8ba. Original filing quantities, metadata and row attribution checked. Holdings facts only; corporate-action and period comparisons are not reviewed. This is AI review, not a human or private-account audit.

Corrections preserve the original record.Suggest a correction ↗

BUILT WITH YOUR INPUT

Your comments help
HoldingsAtlas grow.

Tell us what is useful, what is missing and what we could do better. Your feedback matters.

Visit the feedback page ↗

Copy a dated citation.

English factual summary

DME Capital Management, LP reported 2,335,540 shares of COYA — COYA THERAPEUTICS INC as of 2026-03-31. Reported value: $9,202,027. Weight: 0.29% of Calculated: issuer/class value divided by the complete original reported table; not personal wealth. This is a dated quarter-end position, not a live position, purchase cost or the associated person’s personal account. Filing type: 13F HOLDINGS REPORT. Original rows also reference these included managers: DME Advisors, LP. Manager references describe reported investment discretion, not beneficial ownership.
Source: U.S. SEC EDGAR — https://www.sec.gov/Archives/edgar/data/1489933/000117266126002341/infotable.xml | Published: 2026-05-15 | Collected: 2026-10-20T16:16:14.630Z
Record: https://holdingsatlas.com/records/924aeb05-2a69-49f3-99d5-2534ed463510/

If copying is unavailable, select the text above and copy it manually.